WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 327027

CAS#: 1616493-44-7

Description: Tucidinostat (also known as HBI-8000, Chidamide, and CS-055) is a benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Tucidinostat selectively binds to and inhibits HDAC leading to an increase of acetylation levels of histone protein H3. This agent also inhibits the expression of signaling kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells.

Chemical Structure

CAS# 1616493-44-7

Theoretical Analysis

MedKoo Cat#: 327027
Name: Tucidinostat
CAS#: 1616493-44-7
Chemical Formula: C22H19FN4O2
Exact Mass: 390.1492
Molecular Weight: 390.4184
Elemental Analysis: C, 67.68; H, 4.91; F, 4.87; N, 14.35; O, 8.20

Price and Availability

Size Price Availability Quantity
50.0mg USD 450.0 2 Weeks
100.0mg USD 750.0 2 Weeks
200.0mg USD 1350.0 2 Weeks
500.0mg USD 2850.0 2 Weeks
1.0g USD 3950.0 2 Weeks
2.0g USD 6450.0 2 Weeks
Bulk inquiry

Related CAS #: 1883690-47-8   1616493-44-7   743420-02-2   Tucidinostat HCl    

Synonym: Tucidinostat; HBI-8000; HBI 8000; HBI8000 Chidamide; CS-055; CS 055; CS055; Epidaza

IUPAC/Chemical Name: (E)-N-(2-amino-4-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide


InChi Code: InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 390.4184 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message

Sent On: Wed Apr 15 21:45:20 2020

20 selected items

PubMed Results
Items 1-20 of 20 (Display the 20 citations in PubMed)

1: Zhou H, Han L, Wang H, Wei J, Guo Z, Li Z. Chidamide Inhibits Glioma Cells by Increasing Oxidative Stress via the miRNA-338-5p Regulation of Hedgehog Signaling. Oxid Med Cell Longev. 2020 Mar 11;2020:7126976. doi: 10.1155/2020/7126976. PMID: 32256960; PMCID: PMC7086450.

2: Tian Y, Xie Z, Liao C. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors. Bioorg Med Chem Lett. 2020 Apr 15;30(8):127036. doi: 10.1016/j.bmcl.2020.127036. Epub 2020 Feb 14. PMID: 32088129.

3: Pojani E, Barlocco D. Romidepsin (FK228), An Histone Deacetylase Inhibitor, and its Analogues in Cancer Chemotherapy. Curr Med Chem. 2020 Feb 2. doi: 10.2174/0929867327666200203113926. Epub ahead of print. PMID: 32013816.

4: Guan XW, Wang HQ, Ban WW, Chang Z, Chen HZ, Jia L, Liu FT. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death Dis. 2020 Jan 6;11(1):20. doi: 10.1038/s41419-019-2210-0. PMID: 31907371; PMCID: PMC6944697.

5: Li HY, Jiang FQ, Chu L, Wei X. Long non-coding RNA BLACAT1 inhibits prostate cancer cell proliferation through sponging miR-361. Eur Rev Med Pharmacol Sci. 2020 Jan;24(1):74-85. doi: 10.26355/eurrev_202001_19897. PMID: 31957820.

6: Liu S, Wang Y, Hu T, Zhang C, Zheng Z. Peripheral T cell lymphoma coexisting with Castleman's disease: A case report and literature review. Medicine (Baltimore). 2020 Jan;99(2):e18650. doi: 10.1097/MD.0000000000018650. PMID: 31914048; PMCID: PMC6959880.

7: Xu F, Guo H, Shi M, Liu S, Wei M, Sun K, Chen Y. A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukemia cell lines. Am J Transl Res. 2019 Dec 15;11(12):7644-7655. PMID: 31934307; PMCID: PMC6943475.

8: Wu Y, Wang L, Huang Y, Chen S, Wu S, Dong G, Sheng C. Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide. ACS Med Chem Lett. 2019 Dec 13;11(1):40-44. doi: 10.1021/acsmedchemlett.9b00407. PMID: 31938461; PMCID: PMC6956351.

9: Chi Z, Gao H, Liu H, Wu B, Zhang B, Gu M, Yang W. Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells. Mol Med Rep. 2020 Feb;21(2):936-944. doi: 10.3892/mmr.2019.10873. Epub 2019 Dec 10. PMID: 31974619.

10: Huang H, Wenbing Y, Dong A, He Z, Yao R, Guo W. Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels. Front Oncol. 2019 Dec 3;9:1276. doi: 10.3389/fonc.2019.01276. PMID: 31850196; PMCID: PMC6901797.

11: Guan W, Jing Y, Dou L, Wang M, Xiao Y, Yu L. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia. Leuk Lymphoma. 2020 Apr;61(4):855-861. doi: 10.1080/10428194.2019.1691195. Epub 2019 Nov 22. PMID: 31755348.

12: Ye J, Zha J, Shi Y, Li Y, Yuan D, Chen Q, Lin F, Fang Z, Yu Y, Dai Y, Xu B. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. Clin Epigenetics. 2019 Oct 7;11(1):137. doi: 10.1186/s13148-019-0723-0. PMID: 31590682; PMCID: PMC6781368.

13: Zhang H, Zhang Z, Wang D. Epigenetic regulation of IncRNA KCNKI5-ASI in gastric cancer. Cancer Manag Res. 2019 Sep 20;11:8589-8602. doi: 10.2147/CMAR.S186002. PMID: 31572012; PMCID: PMC6759217.

14: Huang T, Fu Y, Wang S, Xu M, Yin X, Zhou M, Wang X, Chen C. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation. Biomed Pharmacother. 2019 Nov;119:109413. doi: 10.1016/j.biopha.2019.109413. Epub 2019 Sep 10. PMID: 31518872.

15: Wu RJ, Zheng RJ, Huang YQ, Ma XD. [Chidamide combined with chemotherapy for treatment of therapy-related acute myeloid leukemia secondary to peripheral T-cell lymphoma: a case report and literatures review]. Zhonghua Xue Ye Xue Za Zhi. 2019 Aug 14;40(8):685-687. Chinese. doi: 10.3760/cma.j.issn.0253-2727.2019.08.013. PMID: 31495139.

16: Ma Z, Hu P, Guo C, Wang D, Zhang X, Chen M, Wang Q, Sun M, Zeng P, Lu F, Sun L, She L, Zhang H, Yao J, Yang F. Folate-mediated and pH-responsive chidamide- bound micelles encapsulating photosensitizers for tumor-targeting photodynamic therapy. Int J Nanomedicine. 2019 Jul 22;14:5527-5540. doi: 10.2147/IJN.S208649. PMID: 31413561; PMCID: PMC6661377.

17: Bai X, Jiang H, Han G, He Q. Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR‑33a‑5p‑LDHA axis. Mol Med Rep. 2019 Aug;20(2):1857-1865. doi: 10.3892/mmr.2019.10425. Epub 2019 Jun 25. PMID: 31257519.

18: Yuan XG, Huang YR, Yu T, Jiang HW, Xu Y, Zhao XY. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner. Oncol Lett. 2019 Jul;18(1):411-419. doi: 10.3892/ol.2019.10301. Epub 2019 May 2. PMID: 31289512; PMCID: PMC6540238.

19: Che Y, Ding X, Song J, Zhang X, Sun X, Xu L. Effective remission of chidamide on treatment of advanced mycosis fungoides: An unusual case report. Dermatol Ther. 2019 Jul;32(4):e12944. doi: 10.1111/dth.12944. Epub 2019 May 2. PMID: 31012254.

20: Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, Cristofanilli M, Ning Z, Lu X. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27. PMID: 31036468.